Researchers report on a study investigating effects of ADT on prostate cancer health-related quality of life, sexual function, sexual bother, and mood for patients with prostate cancer and their partners.
ADT recipients reported worse subjective sleep disturbance, researchers found.
Aggressive therapy does not appear to be more beneficial than conservative androgen deprivation therapy alone, according to a study.
The risk of cardiovascular disease such as heart failure, arrhythmias, and conduction disorders are greater in men with localized prostate cancer who were treated with androgen deprivation therapy.
Osteoporosis medications were found to reduce bone mineral density loss and risk of fracture in men with nonmetastatic prostate cancer being treated with androgen-deprivation therapy.
Prehabilitation before initiating ADT in older men with prostate cancer may improve functioning, even in men on short-term ADT.
Abiraterone acetate and prednisone reduced PSA levels in a small group of clinical trial participants with metastatic prostate cancer who did not initially respond to ADT.
The long-term use of androgen deprivation therapy (ADT) for up to 36 months does not appear to be associated with cognitive decline in patients with prostate cancer.
The second-generation hsp90 inhibitor onalespib may be beneficial for men with prostate cancer that no longer responds to androgen deprivation therapy
A total of 40% of patients with mCRPC treated with docetaxel after abiraterone achieved at least a 50% reduction in PSA, according to a study presented at the 2016 Genitourinary Cancers Symposium.
Gonadotropin-releasing hormone agonist (GnRHa) therapy is associated with increased risks of numerous clinically relevant adverse events compared with orchiectomy.
A study compared the number of adverse events caused by both intermittent and continuous androgen-deprivation therapy (ADT) for prostate cancer.
In a study that demonstrates the emerging technique of extracting biomedical data from ordinary patient medical records, a nearly 2-fold increase was seen in the rate of Alzheimer disease diagnoses among men with prostate cancer who received ADT.
Men who are receiving androgen deprivation therapy (ADT) have an increased chance of experiencing impaired cognitive function.
Some prostate cancer medications are linked to an increased risk of dying from heart-related causes in men with congestive heart failure or with a history of prior heart attacks.
Androgen deprivation therapy may increase risk of cardiac-related death in patients with cardiac issuesOctober 30, 2014
Men who were treated with androgen deprivation therapy for prostate cancer have a three times increased risk of cardiac problems.
In a study of men with early stage prostate cancer, those who received androgen deprivation as their primary treatment instead of surgery or radiation did not live any longer than those who received no treatment.
The protein SPOP, which is most frequently mutated in human prostate cancers, is a key regulator of androgen receptor activity that prevents uncontrolled growth of cells in the prostate and thus helps prevent cancer.
Androgen deprivation therapy (ADT) was significantly associated with an increased risk for acute kidney injury in a large study of men with nonmetastatic prostate cancer.
Taking a break from hormone-blocking prostate cancer treatments once the cancer seems to be stabilized is not equivalent to continuing therapy, a new large-scale international study finds.
Men with a high risk of bone fracture who are receiving long-term ADT for prostate cancer have a higher fracture incidence after their treatment is completed. Also, men who experienced a fracture had a 1.38-fold higher mortality risk than those who did not.
The FDA has expanded the indication for abiraterone acetate (Zytiga tablets) to combat metastatic castration-resistant prostate cancer.
May accelerate progression in cases of PTEN-loss induced high-grade prostatic intraepithelial.
Optimal treatment of older patients with recurrent prostate cancer now involves more of a decision process than in the past, say the authors of a review article in the journal Drugs & Aging.
Newly approved for prostate cancer, enzalutamide may be useful as a therapeutic agent in breast cancer that evades other treatments.
The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.
Administering radiotherapy after prostatectomy helped nearly two-thirds of users in a recent study remain free of prostate cancer after 10 years.
Certain analyses of cancer cells isolated from the blood could guide decisions about the ideal treatment for a patient with metastatic prostate cancer who has stopped responding to initial therapy.
State of androgen receptor signaling may help determine best treatment.
Intermittent androgen deprivation was just as effective as continuous therapy in overall survival, and improved some quality-of-life factors.
Sign Up for Free e-newsletters
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- The Caregivers' Cancer Journey
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era
- Survey of ACEP Councilors Reveals NP, PA Staffing Models, Practice Patterns Vary
- Breath Analysis May Be an Effective Diagnostic for Pancreatic Cancer
- Genetic Susceptibility to Pancreatic Cancer Linked to 6 Specific Gene Mutations
- Dinner Hour and Sleep Habits Affect Risk of Breast, Prostate Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|